Factors associated with biochemical remission after microscopic transsphenoidal surgery for acromegaly

Hai Sun, Jessica Brzana, Christine (Chris) Yedinak, Sakir Gultekin, Johnny B. Delashaw, Maria Fleseriu

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objectives To analyze surgical outcomes and predictive factors of disease remission in acromegaly patients who underwent microscopic transsphenoidal surgery (TSS) for a growth hormone (GH)-secreting adenoma. Design A 6-year retrospective review of 86 consecutive acromegaly surgeries. Setting Procedures performed at a single institution by a single surgeon. Participants Seventy acromegaly patients. Main Outcome Measures Demographic information, preoperative laboratory values, tumor imaging data, and morphological and immunohistochemical data were collected. Predictive values using the latest and most stringent biochemical remission criteria were determined using univariate and multivariate statistical analyses. Results Remission rate for 59 (18 males) acromegaly patients meeting the study inclusion criteria was 52.5%. Remission rates for micro- and macroadenomas were 81.8% and 45.8%, respectively. Patients of older age, with a smaller tumor, lower Knosp grade, lower preoperative GH, and insulinlike growth factor 1 levels were more likely to achieve remission. Remission rate decreased significantly with repeat surgeries. Those patients with adenomas that stained positive for somatostatin receptor subtype 2A were less likely to experience tumor recurrence and more likely to respond to medical treatment with persistent or elevated GH hypersecretion. Conclusions Microscopic TSS continues to be a viable means for treating acromegaly patients. Patients should be followed long term.

Original languageEnglish (US)
Pages (from-to)47-52
Number of pages6
JournalJournal of Neurological Surgery, Part B: Skull Base
Volume75
Issue number1
DOIs
StatePublished - Feb 2014

Fingerprint

Acromegaly
Growth Hormone
Adenoma
Neoplasms
Reoperation
Intercellular Signaling Peptides and Proteins
Multivariate Analysis
Demography
Outcome Assessment (Health Care)
Recurrence

Keywords

  • acromegaly
  • remission
  • transsphenoidal surgery

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Factors associated with biochemical remission after microscopic transsphenoidal surgery for acromegaly. / Sun, Hai; Brzana, Jessica; Yedinak, Christine (Chris); Gultekin, Sakir; Delashaw, Johnny B.; Fleseriu, Maria.

In: Journal of Neurological Surgery, Part B: Skull Base, Vol. 75, No. 1, 02.2014, p. 47-52.

Research output: Contribution to journalArticle

@article{94109a03c3b64efbbdfbe009f177ed3b,
title = "Factors associated with biochemical remission after microscopic transsphenoidal surgery for acromegaly",
abstract = "Objectives To analyze surgical outcomes and predictive factors of disease remission in acromegaly patients who underwent microscopic transsphenoidal surgery (TSS) for a growth hormone (GH)-secreting adenoma. Design A 6-year retrospective review of 86 consecutive acromegaly surgeries. Setting Procedures performed at a single institution by a single surgeon. Participants Seventy acromegaly patients. Main Outcome Measures Demographic information, preoperative laboratory values, tumor imaging data, and morphological and immunohistochemical data were collected. Predictive values using the latest and most stringent biochemical remission criteria were determined using univariate and multivariate statistical analyses. Results Remission rate for 59 (18 males) acromegaly patients meeting the study inclusion criteria was 52.5{\%}. Remission rates for micro- and macroadenomas were 81.8{\%} and 45.8{\%}, respectively. Patients of older age, with a smaller tumor, lower Knosp grade, lower preoperative GH, and insulinlike growth factor 1 levels were more likely to achieve remission. Remission rate decreased significantly with repeat surgeries. Those patients with adenomas that stained positive for somatostatin receptor subtype 2A were less likely to experience tumor recurrence and more likely to respond to medical treatment with persistent or elevated GH hypersecretion. Conclusions Microscopic TSS continues to be a viable means for treating acromegaly patients. Patients should be followed long term.",
keywords = "acromegaly, remission, transsphenoidal surgery",
author = "Hai Sun and Jessica Brzana and Yedinak, {Christine (Chris)} and Sakir Gultekin and Delashaw, {Johnny B.} and Maria Fleseriu",
year = "2014",
month = "2",
doi = "10.1055/s-0033-1354578",
language = "English (US)",
volume = "75",
pages = "47--52",
journal = "Journal of Neurological Surgery, Part B: Skull Base",
issn = "2193-6331",
publisher = "Thieme Medical Publishers",
number = "1",

}

TY - JOUR

T1 - Factors associated with biochemical remission after microscopic transsphenoidal surgery for acromegaly

AU - Sun, Hai

AU - Brzana, Jessica

AU - Yedinak, Christine (Chris)

AU - Gultekin, Sakir

AU - Delashaw, Johnny B.

AU - Fleseriu, Maria

PY - 2014/2

Y1 - 2014/2

N2 - Objectives To analyze surgical outcomes and predictive factors of disease remission in acromegaly patients who underwent microscopic transsphenoidal surgery (TSS) for a growth hormone (GH)-secreting adenoma. Design A 6-year retrospective review of 86 consecutive acromegaly surgeries. Setting Procedures performed at a single institution by a single surgeon. Participants Seventy acromegaly patients. Main Outcome Measures Demographic information, preoperative laboratory values, tumor imaging data, and morphological and immunohistochemical data were collected. Predictive values using the latest and most stringent biochemical remission criteria were determined using univariate and multivariate statistical analyses. Results Remission rate for 59 (18 males) acromegaly patients meeting the study inclusion criteria was 52.5%. Remission rates for micro- and macroadenomas were 81.8% and 45.8%, respectively. Patients of older age, with a smaller tumor, lower Knosp grade, lower preoperative GH, and insulinlike growth factor 1 levels were more likely to achieve remission. Remission rate decreased significantly with repeat surgeries. Those patients with adenomas that stained positive for somatostatin receptor subtype 2A were less likely to experience tumor recurrence and more likely to respond to medical treatment with persistent or elevated GH hypersecretion. Conclusions Microscopic TSS continues to be a viable means for treating acromegaly patients. Patients should be followed long term.

AB - Objectives To analyze surgical outcomes and predictive factors of disease remission in acromegaly patients who underwent microscopic transsphenoidal surgery (TSS) for a growth hormone (GH)-secreting adenoma. Design A 6-year retrospective review of 86 consecutive acromegaly surgeries. Setting Procedures performed at a single institution by a single surgeon. Participants Seventy acromegaly patients. Main Outcome Measures Demographic information, preoperative laboratory values, tumor imaging data, and morphological and immunohistochemical data were collected. Predictive values using the latest and most stringent biochemical remission criteria were determined using univariate and multivariate statistical analyses. Results Remission rate for 59 (18 males) acromegaly patients meeting the study inclusion criteria was 52.5%. Remission rates for micro- and macroadenomas were 81.8% and 45.8%, respectively. Patients of older age, with a smaller tumor, lower Knosp grade, lower preoperative GH, and insulinlike growth factor 1 levels were more likely to achieve remission. Remission rate decreased significantly with repeat surgeries. Those patients with adenomas that stained positive for somatostatin receptor subtype 2A were less likely to experience tumor recurrence and more likely to respond to medical treatment with persistent or elevated GH hypersecretion. Conclusions Microscopic TSS continues to be a viable means for treating acromegaly patients. Patients should be followed long term.

KW - acromegaly

KW - remission

KW - transsphenoidal surgery

UR - http://www.scopus.com/inward/record.url?scp=84893815913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893815913&partnerID=8YFLogxK

U2 - 10.1055/s-0033-1354578

DO - 10.1055/s-0033-1354578

M3 - Article

VL - 75

SP - 47

EP - 52

JO - Journal of Neurological Surgery, Part B: Skull Base

JF - Journal of Neurological Surgery, Part B: Skull Base

SN - 2193-6331

IS - 1

ER -